Cedar Mundi Ventures specializes in the fields of venture capital and financial services. It also specializes in cross-border technology investments covering Europe & the MENA region. It was founded in 2016 and headquartered in Beyrouth, Lebanon.

Cedar Mundi Ventures

BECO Capital provides growth capital and hands-on operational support for early-stage technology companies. It is a technology-focused venture capital that supports entrepreneurs and financial sectors to raise funds. The company helps small companies with growth capital and hands-on operational mentorship in their early stage of development. It was founded in 2012 and is based in Dubai, United Arab Emirates. BECO Capital was founded on February 1, 2014, by Dany Farha and Amir Farha, and it is headquartered in Dubai.

BECO Capital

Global Ventures is an international venture capital firm, investing in founders and ideas across emerging markets. The Global Ventures team is a diverse, collaborative, talented, and curious group of professionals who, combined, have years of experience and expertise building and scaling companies.

Global Ventures

Draper Associates is an early-stage venture capital firm that invests in industry-transforming companies. They invest globally, in great teams of people creating revolutionary companies in new media, gaming, SaaS, cloud, new finance, IOT, and mobile. Their portfolio companies disrupting markets in the tens of billions and are on a clear path to later rounds of fundraising. Draper Associates encourages entrepreneurs to drive their businesses to greatness, to transform industries with new technologies, and to build platforms for extraordinary growth, jobs, and wealth creation. It was founded in 2015 and is headquartered in San Mateo, CA, USA.

Draper Associates

Endeavor Catalyst is the co-investment fund set up to invest exclusively in led companies and to sustain Endeavor’s long-term operations in a mission-aligned way.

Endeavor Catalyst

Bossa Invest manages investment portfolios and provides asset management services to clients. It analyzes market trends to inform investment decisions. Bossa Invest serves multiple sectors, including finance, technology, and real estate.

Bossa Invest

Maverick Ventures is the venture arm of multi-billion dollar investment firm Maverick Capital. Combining the resources of a global firm with the benefits of an agile, focused team, Maverick Ventures supports entrepreneurs from seed through maturity. With over 30 years of early-stage investment experience, the Maverick Ventures team has funded more than 100 companies in the healthcare, software and deep technology sectors. The highly-experienced team of operating executives and investors at Maverick Ventures generally lead rounds, take board seats and work with management to build successful enterprises.

Maverick Ventures

Eight Roads Ventures is a global venture capital firm managing $11bn of assets across offices in the UK, China, India, Japan, and the US. Together with our associated funds, including our US sister fund F-Prime Capital, our 50-year history of investing includes partnerships with over 500 companies such as Alibaba, AppsFlyer, Chewy, Fareye, Fever, Flywire, Fireblocks, Funnel.io, Gloat, Hibob, Icertis, Neo4j, Otrium, Owkin, Paidy, Spendesk, Tibber, Toast, Wallapop and Xoom.

Eight Roads Ventures

F-Prime's roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, this venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.  Today, F-Prime's funds are larger and more global, but its teams are still small and local. F-Prime stays true to its entrepreneurial roots. In the US and Europe, F-Prime Capital Partners is investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, its sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai.   Together F-Prime brings a world of insight, domain expertise and relationships to support entrepreneurs. Without the pressure of fundraising from outside investors, F-Prime Capital Partners focuses all of its time finding and helping great entrepreneurs build important companies.

F-Prime Capital

Questa Capital Management is a healthcare venture growth equity firm investing in breakout growth companies. Questa seeks out disruptive business models that improve lives and provide better quality and more efficient care. They partner with superior management teams to help build innovative market leaders. Questa Capital Management's mission is to generate outstanding returns for investors and management teams.

Questa Capital Management

Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences, principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

Advent Life Sciences

Emerson Collective is an organization dedicated to removing barriers to opportunity so people can live to their full potential. Established and led by Laurene Powell Jobs, we center our work on education, immigration reform, the environment, and other social justice initiatives. We use a wide range of tools and strategies—partnering with entrepreneurs and experts, parents and policymakers, advocates and administrators—to develop and execute innovative solutions that will spur change and promote equality.

Emerson Collective

SoftBank Vision Fund is a subsidiary of Softbank Group that specializes in growth capital and social impact investments. Sectors that the fund invests in include the internet of things, artificial intelligence (AI), robotics, communications infrastructure, telecoms, computational biology, biotech, cloud technologies and software, consumer internet businesses, financial technology, and mobile apps. The Fund is designed to be a catalyst for technology progress in anticipation that it will expand SoftBank's capabilities, accelerating progress towards SoftBank 2.0. It aims to invest in businesses and foundational platforms that SoftBank believes to revolutionize and innovate the world tomorrow.

SoftBank Vision Fund

British Patient Capital invests in a diversified portfolio of best-in-class venture and growth capital funds and start ups, capturing value through financing the growth of innovative companies. We invest on a commercial basis to deliver competitive returns and manage risk. As well as providing our own funding we work to encourage more investors to make allocations to this asset class by demonstrating that a long-term patient capital investment strategy can produce commercially attractive returns. Once we’ve established a strong record, and have proved the value of the asset class, we intend to privatise British Patient Capital at an appropriate time in the future.

British Patient Capital

Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for its shareholder, the Government of Abu Dhabi. Mubadala’s US $229 billion portfolio spans five continents with interests in multiple sectors including aerospace, ICT, semiconductors, metals and mining, renewable energy, oil and gas, petrochemicals, utilities, healthcare, real estate, pharmaceuticals and medical technology, agribusiness and a global portfolio of financial holdings across all asset classes. Mubadala has offices in Rio de Janeiro, Moscow, New York, and San Francisco, with a joint venture in Hong Kong. Mubadala is a trusted partner, an engaged shareholder and a responsible global company that is committed to world-class standards of governance.

Mubadala

Minderoo aims to empower both our employees and others to have a positive impact through inclusion, collaboration, and, most importantly, kindness. The world needs more of it. They are a philanthropic fundraising service.

Minderoo Foundation

Proximie

Proximie is a health technology platform that enables surgeons to virtually attend operating theaters to visually guide complex surgeries. Proximie combines human expertise with the power of augmented reality, artificial intelligence, and machine learning to allow a surgeon to remotely watch an operation and use their hands to demonstrate things to the surgeon conducting the operation, who sees the remote surgeon on a screen. This platform aims to democratize access to the most up-to-date and skilled knowledge on surgery practice, by helping surgeons advise each other from different parts of the world. The company was founded by Nadine Hachach-Haram in 2016 and is headquartered in London, England.

Proximie is a health technology platform that combines telepresence, augmented reality (AR), machine learning, and AI to enable surgeons to virtually "scrub in" to any operating room from anywhere in the world. The company's core product is a web-based software that allows surgeons to collaborate remotely by sharing live video streams of surgeries from up to four camera perspectives, along with medical scans. Its AR tools enable surgeons to draw instructions or annotations on the shared screen, providing real-time guidance during procedures.

The Daring Robot Surgery That Saved a Man’s Life

Proximie lands $38M for tech that helps surgeons virtually join operations

10 Augmented Reality Surgery Companies

Global Health Technology Platform Provider Proximie Commences Rollout of PxLens Using Vuzix M4000™ Smart Glasses

HOW IS THIS LEBANESE ENTREPRENEUR USING REMOTE SURGERY TO DISRUPT GLOBAL HEALTHCARE

Proximie secures $80M to expand platform that connects surgeons virtually to operating rooms

The leading healthcare platform for improving patient outcomes and driving productivity.

Teladoc adds feature to bring surgical support from afar

Proximie Rolls Out Smart Glasses Solution for Operating Rooms

Smith+Nephew & leading HealthTech - Proximie - partner to deliver advanced robotics surgery training

SoftBank backs Proximie in $80m round for AR surgery

Proximie raises $80M in Series C funding to scale its connected surgical care platform that combines AI, ML and AR

Proximie Raised $80M for Its AR

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Olympus, Proximie Team Up for Telecollaboration in the OR

Olympus

To enable real-time collaboration and knowledge sharing in operating rooms.



Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Vodafone

Proximie, a medical technology platform, partnered with Vodafone to leverage its 5G, IoT and edge computing infrastructure to expand its business

Generating, collecting, and analyzing enterprise data will never be the same.

Edge Computing

Companies that provide software to enable users to run their applications at the edge.

Teladoc Health

To integrate Proximie software in Teladoc Health's Solo™ platform ecosystem for hospitals and health systems, enabling an integrated experience for surgeons.

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

Primary care through virtual consultations for general health-related concerns using a digital platform or mobile app.

Proximie is a health technology platform that combines telepresence, augmented reality (AR), machine learning, and AI to enable surgeons to virtually "scrub in" to any operating room from anywhere in the world. The company's core product is a web-based software that allows surgeons to collaborate remotely by sharing live video streams of surgeries from up to four camera perspectives, along with medical scans. Its AR tools enable surgeons to draw instructions or annotations on the shared screen, providing real-time guidance during procedures.Founded in 2016 by Dr. Nadine Hachach-Haram, a plastic surgeon, the device-agnostic platform also captures data from procedures, creating a secure library that can be used for training, debriefing, and advancing surgical techniques.Key customers and partnershipsAs of November 2024, Proximie was used in 800+ hospitals across 50+ countries. The company had partnered with major healthcare providers, medical device companies, and educational institutions.In<a href="https://sp-edge.com/updates/35183"> October 2024</a>, the company partnered with Olympus to enable real-time collaboration and knowledge sharing in operating rooms.

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

PROMINENT_CATEGORY

<div>
 
 Proximie, a health technology platform, has partnered with Olympus to facilitate live collaboration and knowledge sharing in operating rooms. The integration enables physicians to share live audio, video, and imagery from surgeries with global teams via Proximie's cloud-based platform. Its features include high-definition video streaming, annotation tools, and content management capabilities, all accessible from any internet-enabled device.
 
</div>

Proximie

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless